The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Industry s Direct’s proprietary databases, Firms ’s corporate website, SEC filings, investor presentations and featured press releases, both from industry player and market -specific third party sources, put together by Global Industry s Direct’s team.

Scope of the Research

- ARCAGY/ GINECO GROUP - Brief industry player overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of ARCAGY/ GINECO GROUP human therapeutic division.
- Detailed Analysis of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of ARCAGY/ GINECO GROUP with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the ARCAGY/ GINECO GROUP’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Why Should You Get This Report?

- Evaluate ARCAGY/ GINECO GROUP’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of ARCAGY/ GINECO GROUP in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the ARCAGY/ GINECO GROUP’s Research and Development portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with ARCAGY/ GINECO GROUP.
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of ARCAGY/ GINECO GROUP and identify potential opportunities in those areas.

Table Of Contents

Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
ARCAGY - GINECO Snapshot 5
Key Information 5
Key Facts 5
ARCAGY - GINECO - Research and Development Overview 6
Key Therapeutic Areas 6
ARCAGY - GINECO - Pipeline Review 9
Pipeline Products by Stage of Development 9
Pipeline Products - Monotherapy 10
Pipeline Products - Combination Treatment Modalities 11
ARCAGY - GINECO - Pipeline Products Glance 12
ARCAGY - GINECO - Late Stage Pipeline 12
Phase III Products/Combination Treatment Modalities 12
ARCAGY - GINECO Clinical Stage Pipeline Products 13
Phase II Products/Combination Treatment Modalities 13
ARCAGY - GINECO - Drug Profiles 14
Aromasin + Celebrex 14
Product Description 14
Mechanism of Action 14
RandD Progress 14
pegylated liposomal doxorubicin hydrochloride + Carboplatin 15
Product Description 15
Mechanism of Action 15
RandD Progress 15
Bevacizumab + Paclitaxel + Capecitabine 16
Product Description 16
Mechanism of Action 16
RandD Progress 17
Paclitaxel + Capecitabine 18
Product Description 18
Mechanism of Action 18
RandD Progress 18
Paclitaxel + Carboplatin 20
Product Description 20
Mechanism of Action 20
RandD Progress 20
Paclitaxel + Carboplatin 21
Product Description 21
Mechanism of Action 21
RandD Progress 21
paclitaxel + topotecan 22
Product Description 22
Mechanism of Action 22
RandD Progress 22
Paraplatin + Paclitaxel 23
Product Description 23
Mechanism of Action 23
RandD Progress 23
Pegylated liposomal doxorubicin + Docetaxel 24
Product Description 24
Mechanism of Action 24
RandD Progress 24
Revlimid 25
Product Description 25
Mechanism of Action 25
RandD Progress 25
ARCAGY - GINECO - Pipeline Analysis 26
ARCAGY - GINECO - Pipeline Products by Therapeutic Class 26
ARCAGY - GINECO Pipeline Products By Target 28
ARCAGY - GINECO - Pipeline Products by Route of Administration 30
ARCAGY - GINECO - Pipeline Products by Molecule Type 31
ARCAGY - GINECO - Dormant Projects 32
ARCAGY - GINECO - Locations And Subsidiaries 33
Head Office 33
Appendix 34
Methodology 34
Coverage 34
Secondary Research 34
Primary Research 34
Expert Panel Validation 35
Contact Us 35
Disclaimer 35List of Tables
ARCAGY - GINECO - Pipeline by Therapy Area and Indication, 2010 8
ARCAGY - GINECO - Pipeline by Stage of Development, 2010 9
ARCAGY - GINECO - Monotherapy Products in Pipeline, 2010 10
ARCAGY - GINECO - Combination Treatment Modalities in Pipeline, 2010 11
ARCAGY - GINECO - Phase III, 2010 12
ARCAGY - GINECO - Phase II, 2010 13
ARCAGY - GINECO - Pipeline By Therapeutic Class, 2010 26
ARCAGY - GINECO - Pipeline By Target, 2010 29
ARCAGY - GINECO - Pipeline By Route of Administration, 2010 30
ARCAGY - GINECO - Pipeline By Molecule Type, 2010 31
ARCAGY - GINECO - Dormant Developmental Projects, 2010 32

List of Figures
ARCAGY - GINECO - Pipeline by Therapy Area and Indication, 2010 7
ARCAGY - GINECO - Pipeline by Stage of Development, 2010 9
ARCAGY - GINECO - Monotherapy Products in Pipeline, 2010 10
ARCAGY - GINECO - Combination Treatment Modalities in Pipeline, 2010 11
ARCAGY - GINECO - Pipeline By Therapeutic Class, 2010 26
ARCAGY - GINECO - Pipeline By Target, 2010 28
ARCAGY - GINECO - Pipeline By Route of Administration, 2010 30

View This Report »

Find all the market research you need - instantly, in one place.

+1.2 Million Research Documents & Statistics +200,000 Trusted Public Sources 350 Industries With Global Coverage

24/7 Customer Support

Talk to Louis

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers

Therapeutics for Women%s Health: Technologies and Global Markets

Therapeutics for Women%s Health: Technologies and Global Markets

  • $ 6 650
  • Industry report
  • May 2014
  • by BCC Research

Use this report to: - Learn about the main women's health disorders and relevant disease prevalence population. - Identify the impact of demographic, economic, and other factors that will drive future ...

Chronic Lymphocytic Leukaemia: KOL Insight

Chronic Lymphocytic Leukaemia: KOL Insight

  • $ 5 369
  • Industry report
  • May 2014
  • by Firstword Pharma

Chronic lymphocytic leukaemia (CLL) is the most common of the leukaemias, but until recently it has been underserved in terms of effective therapeutic options. However, a revolution in personalised and ...

ADHD Therapeutics to 2020 - Broadened Diagnostic Criteria and Growing Adult Prevalence to Drive Market Growth despite Patent Expirations

ADHD Therapeutics to 2020 - Broadened Diagnostic Criteria and Growing Adult Prevalence to Drive Market Growth despite Patent Expirations

  • $ 4 995
  • Industry report
  • July 2014
  • by GBI Research

ADHD Therapeutics to 2020 - Broadened Diagnostic Criteria and Growing Adult Prevalence to Drive Market Growth despite Patent Expirations Summary GBI Research has released the pharma report, “ADHD Therapeutics ...


ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - quickly, in one place.